ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI In November

December 28, 2001

Six Comprehensive Center Asked By Candlelighters For Pediatric Cancer

March 24, 1978

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

November 29, 2002

Justice Department Clears SWOG Study Of Breast Cancer Treatment Costs

November 17, 1995

BSA Strikes Down NCI Tissue Bank Plan, Calls for Audit of caBIG

March 11, 2011

FDA Hazleton Probe Finds Some Problems; Results Unaffected

April 23, 1976